Inovio Pharma Begins Phase 2 Clinical Trial To Evaluate Leukemia DNA Vaccine

Inovio Pharmaceuticals, Inc. (INO: News ) Monday announced the regulatory approval of a Phase 2 clinical trial to treat leukemia utilizing Inovio's new ELGEN 1000 automated vaccine delivery device.

The pharmaceutical company stated that the open-label, multi-center clinical trial being run by the University of Southampton is evaluating a DNA vaccine to treat chronic myeloid leukemia and acute myeloid leukemia.

Leukemia is a malignant disease or cancer of the bone marrow and blood characterized by the uncontrolled accumulation of blood cells, accounting for at least 300,000 new cases and 222,000 deaths worldwide each year.

No comments:

Post a Comment

Superhit News

News Archive